Ginkgo Bioworks Holdings, Inc. is engaged in building the horizontal platform for cell programming. The Company’s platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products such as therapeutics, key food ingredients, and chemicals derived from petroleum. The Company operates through two segments: Foundry and Biosecurity. Foundry consists of research and development services performed under collaboration and license agreements relating to the Company’s cell programming platform. Its cell programming platform includes two assets: the Foundry, biology lab facilities, enabled by investment in workflows, custom software, robotic automation, and data science and analytics, which is paired with the Company’s Codebase, a collection of biological parts and a database of biological data used to program cells. Biosecurity consists of COVID-19 testing products and services primarily provided to public health authorities.